CDK

ZK 304709 is a multi-target cyclin-dependent kinase (CDK) inhibitor that plays a critical role in cell cycle regulation. It effectively inhibits various CDKs, thereby preventing proliferation in cancer cells. This compound is valuable for studying mechanisms of cell cycle control and can aid in the development of novel therapeutic strategies against cancer.

CDK9-IN-34 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9) with an IC50 value of 0.25 μM. It demonstrates significant cytotoxic effects on cancer cell lines HCT116, MCF7, and K652, with IC50 values of 1.43 μM, 3.01 μM, and 50.27 μM, respectively. Additionally, CDK9-IN-34 exhibits antiviral properties against coronavirus 229E, displaying an IC50 of 145.92 μM. This compound serves as a valuable tool for investigating the roles of CDK9 in cancer and viral pathogenesis.

LDC4297 hydrochloride is a selective inhibitor of cyclin-dependent kinase 7 (CDK7), exhibiting an IC50 of 0.13 nM. This compound effectively inhibits human cytomegalovirus (HCMV) replication with an EC50 value of 24.5 nM and demonstrates broad antiviral activity against multiple families of viruses, including Herpesviridae, Adenoviridae, Poxviridae, Retroviridae, and Orthomyxoviridae, with EC50 values ranging from 0.02 to 1.21 μM. LDC4297 hydrochloride is valuable for research into viral infections and the underlying mechanisms of CDK7 in cellular pathways.

CDK9-IN-30 is a selective inhibitor of Cyclin-dependent kinase 9 (CDK9), primarily targeting its role in transcription regulation. This compound exhibits potent antiviral activity by disrupting HIV-1 replication, making it a valuable tool for studying HIV-1 pathogenesis and exploring therapeutic strategies. Its inhibition of CDK9 can also provide insights into broader cellular processes related to transcriptional regulation and oncogenesis.

HZ1 is a selective inhibitor of cyclin-dependent kinase-like 3 (CDKL3) that operates via targeted inhibition of this kinase. It demonstrates significant tumor-suppressive activity and has potential to circumvent resistance to CDK4/6 inhibitors. This compound is applicable in cancer research, particularly in studies focused on cell cycle regulation and therapeutic resistance mechanisms.

Ribociclib succinate is an orally active inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), functioning through ATP-competitive mechanisms. It demonstrates potent activity with IC50 values of 10 nM and 39 nM against CDK4 and CDK6, respectively, while exhibiting over 1,000-fold selectivity against the cyclin B/CDK1 complex. This selectivity makes it a valuable tool in cancer research, particularly in studies targeting cell cycle regulation and therapeutic strategies for hormone receptor-positive breast cancer.

Ribociclib succinate hydrate is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), functioning through competitive inhibition of ATP binding. With IC50 values of 10 nM and 39 nM against CDK4 and CDK6, respectively, it demonstrates significant selectivity over the cyclin B/CDK1 complex. This compound is utilized in cancer research, particularly in studies focusing on cell cycle regulation, tumor proliferation, and the therapeutic potential in various malignancies. Its ability to cross the blood-brain barrier allows for exploration in central nervous system-related cancers.